Welcome Tanja Karvonen!

21.3.2024

Finland: An Ideal Environment for the Pharmaceutical Industry’s Real-World Evidence (RWE) Studies

Pharmaceutical companies should consider Finland when evaluating locations for Real-World Evidence (RWE) studies. The country boasts numerous strengths that make it an outstanding choice for real-world data-based (RWD) research. “Finland’s strong tradition and extensive experience in utilizing healthcare registries for research make it unique,” says Dr. Riikka Mattila, Scientific Advisor at Medaffcon.

18.3.2024

Heikki Koski Appointed as CEO of Medaffcon Oy

Heikki Koski, currently the Service Business and Development Director at Tamro, has been appointed as the CEO of Medaffcon Oy, effective from April 1, 2024. Medaffcon is a subsidiary of Tamro Oyj. The current CEO of Medaffcon, Jarmo Hahl, will continue to play a pivotal role in shaping the company's future in his new position leading the consulting business.

14.3.2024

Medaffcon has in-depth Understanding of the Needs of the Pharmaceutical Industry –

Selecting the right interactions is a key factor for success. Therefore, the client should also consider how well the partner understands the pharmaceutical industry's needs. When the partner has extensive hands-on experience from the industry, these irreplaceable insights enable the partner to guide the project at different strategic levels, ensuring that the client’s various needs can be identified and met.

Cookies

Welcome Tanja Karvonen!

Tanja joined Medaffcon’s Market Access team in November 2016

Related articles

Finland: An Ideal Environment for the Pharmaceutical Industry’s Real-World Evidence (RWE) Studies

Heikki Koski Appointed as CEO of Medaffcon Oy

Medaffcon has in-depth Understanding of the Needs of the Pharmaceutical Industry –